The latest update is out from Invion ( (AU:IVX) ).
Invion Limited has announced the quotation of 7,035,447 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of March 11, 2025. This move is part of a previously announced transaction and could potentially enhance the company’s financial flexibility and market presence, impacting its stakeholders and positioning within the biotechnology sector.
More about Invion
Invion Limited operates in the biotechnology industry, focusing on the development of treatments for chronic inflammatory diseases. The company is primarily involved in the research and development of new therapies and has a market focus on innovative medical solutions.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.65M
Find detailed analytics on IVX stock on TipRanks’ Stock Analysis page.